All In Biotech

Drug Trial Radar · NCT05372367

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid Tumours

Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Aug 11, 2022

Primary completion

Jul 17, 2024

Study completion Apr 29, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open for adults with advanced cancer (solid tumours). This is a study for people for whom previous treatment was not successful. This study tests a medicine called BI 907828. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. The purpose of this study is to find out whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor. This study uses an OATP inhibitor called rifampicin and a CYP3 inhibitor called itraconazole. In clinical practice, rifampicin is used as an antibiotic. Itraconazole is used to treat fungal infections. Participants are divided into 2 groups: a rifampicin group and an itraconazole group. Every participant takes BI 907828 as a tablet every 3 weeks. This is called a cycle. * Rifampicin group: In addition to BI 907828, participants take 1 tablet of rifampicin in the second cycle. * Itraconazole group: In addition to BI 907828, participants take itraconazole tablets for 20 days starting 1 week after the second cycle begins Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors take blood samples from the participants to compare the amount of BI 907828 in the blood when it is taken alone and when participants also take rifampicin. Doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Solid Tumors

Interventions

  • BI 907828Drug

    BI 907828

  • RifampicinDrug

    Rifampicin

  • ItraconazoleDrug

    Itraconazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Group 1: Area under the concentration-time curve of BI 907828 in plasma over the time interval from 0 to 24 hours (AUC 0-24)Time frame: up to 24 hours
  2. Group 1: Maximum measured concentrations of BI 907828 in plasma (C max)Time frame: up to 15 days
  3. Group 2: Area under the concentration-time curve of BI 907828 in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz)Time frame: up to 15 days
  4. Group 2: Maximum measured concentrations of BI 907828 in plasma (C max)Time frame: up to 15 days

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Wilrijk - HOSP GZA (St-Augustinus)

    Wilrijk, Belgium

  • Hospital Quiron. I.C.U.

    Barcelona, Spain

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain

  • Fundación Jiménez Díaz

    Madrid, Spain

  • CIO Clara Campal

    Madrid, Spain

  • Hospital Quirónsalud Madrid

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.